|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C16orf72 |
Gene summary for C16ORF72 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C16orf72 | Gene ID | 29035 |
| Gene name | chromosome 16 open reading frame 72 | |
| Gene Alias | PRO0149 | |
| Cytomap | 16p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q14CZ0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29035 | C16orf72 | LZE4T | Human | Esophagus | ESCC | 1.82e-02 | -1.07e-01 | 0.0811 |
| 29035 | C16orf72 | LZE7T | Human | Esophagus | ESCC | 3.00e-08 | 1.17e-02 | 0.0667 |
| 29035 | C16orf72 | LZE8T | Human | Esophagus | ESCC | 4.26e-06 | 6.63e-02 | 0.067 |
| 29035 | C16orf72 | LZE20T | Human | Esophagus | ESCC | 3.60e-07 | -1.20e-01 | 0.0662 |
| 29035 | C16orf72 | LZE22T | Human | Esophagus | ESCC | 4.31e-05 | -5.91e-02 | 0.068 |
| 29035 | C16orf72 | LZE24T | Human | Esophagus | ESCC | 4.63e-11 | -7.36e-02 | 0.0596 |
| 29035 | C16orf72 | LZE6T | Human | Esophagus | ESCC | 5.87e-04 | -1.51e-01 | 0.0845 |
| 29035 | C16orf72 | P2T-E | Human | Esophagus | ESCC | 3.41e-19 | 2.13e-01 | 0.1177 |
| 29035 | C16orf72 | P4T-E | Human | Esophagus | ESCC | 1.06e-17 | 1.95e-01 | 0.1323 |
| 29035 | C16orf72 | P5T-E | Human | Esophagus | ESCC | 6.86e-18 | 6.68e-02 | 0.1327 |
| 29035 | C16orf72 | P8T-E | Human | Esophagus | ESCC | 8.55e-15 | 3.48e-01 | 0.0889 |
| 29035 | C16orf72 | P9T-E | Human | Esophagus | ESCC | 3.56e-15 | -1.88e-02 | 0.1131 |
| 29035 | C16orf72 | P10T-E | Human | Esophagus | ESCC | 3.81e-16 | 1.53e-02 | 0.116 |
| 29035 | C16orf72 | P12T-E | Human | Esophagus | ESCC | 6.38e-21 | 4.38e-01 | 0.1122 |
| 29035 | C16orf72 | P15T-E | Human | Esophagus | ESCC | 4.48e-14 | 3.51e-01 | 0.1149 |
| 29035 | C16orf72 | P16T-E | Human | Esophagus | ESCC | 7.65e-15 | 5.26e-02 | 0.1153 |
| 29035 | C16orf72 | P17T-E | Human | Esophagus | ESCC | 1.16e-04 | 1.17e-01 | 0.1278 |
| 29035 | C16orf72 | P19T-E | Human | Esophagus | ESCC | 1.13e-02 | -1.22e-01 | 0.1662 |
| 29035 | C16orf72 | P20T-E | Human | Esophagus | ESCC | 1.34e-13 | -3.71e-02 | 0.1124 |
| 29035 | C16orf72 | P21T-E | Human | Esophagus | ESCC | 8.43e-21 | 1.38e-01 | 0.1617 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C16orf72 | SNV | Missense_Mutation | novel | c.329G>A | p.Arg110Gln | p.R110Q | Q14CZ0 | protein_coding | deleterious(0.01) | possibly_damaging(0.82) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| C16orf72 | SNV | Missense_Mutation | novel | c.818G>T | p.Arg273Ile | p.R273I | Q14CZ0 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| C16orf72 | SNV | Missense_Mutation | rs781070790 | c.811C>T | p.Arg271Cys | p.R271C | Q14CZ0 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C16orf72 | SNV | Missense_Mutation | c.671G>A | p.Arg224Gln | p.R224Q | Q14CZ0 | protein_coding | deleterious(0.02) | benign(0.009) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| C16orf72 | SNV | Missense_Mutation | novel | c.368N>A | p.Arg123His | p.R123H | Q14CZ0 | protein_coding | deleterious(0) | probably_damaging(0.938) | TCGA-AA-3833-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C16orf72 | SNV | Missense_Mutation | novel | c.697N>A | p.Asp233Asn | p.D233N | Q14CZ0 | protein_coding | tolerated(0.08) | probably_damaging(0.996) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| C16orf72 | SNV | Missense_Mutation | c.415C>T | p.Arg139Cys | p.R139C | Q14CZ0 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| C16orf72 | SNV | Missense_Mutation | c.599T>C | p.Met200Thr | p.M200T | Q14CZ0 | protein_coding | deleterious(0.01) | probably_damaging(0.946) | TCGA-F4-6703-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| C16orf72 | SNV | Missense_Mutation | novel | c.697N>A | p.Asp233Asn | p.D233N | Q14CZ0 | protein_coding | tolerated(0.08) | probably_damaging(0.996) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| C16orf72 | SNV | Missense_Mutation | c.415N>T | p.Arg139Cys | p.R139C | Q14CZ0 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |